Sci Rep:血清HBcrAg是乙肝HBV-DNA的一种新型标志物!

2017-03-13 MedSci MedSci原创

最近,有一些建议认为乙型肝炎核心相关抗原(HBcrAg)可以作为乙型肝炎病毒(HBV)感染的另一种标记物。近期,一项发表在杂志Sci Rep上的研究旨在探讨血清定量HBcrAg(qHBcrAg)是否为肝内共价闭合环状DNA(cccDNA)的一种替代标志物。此项研究共有139名患者进行肝活检,包括59名免疫耐受(IT)阶段患者,52名免疫清除(IC)阶段患者,18名低复制(LR)阶段患者以及10名重

最近,有一些建议认为乙型肝炎核心相关抗原(HBcrAg)可以作为乙型肝炎病毒(HBV)感染的另一种标记物。


近期,一项发表在杂志Sci Rep上的研究旨在探讨血清定量HBcrAg(qHBcrAg)是否为肝内共价闭合环状DNA(cccDNA)的一种替代标志物。

此项研究共有139名患者进行肝活检,包括59名免疫耐受(IT)阶段患者,52名免疫清除(IC)阶段患者,18名低复制(LR)阶段患者以及10名重新激活阶段患者。所有IC期的患者均接受恩替卡韦(ETV)治疗,其中有32例患者在24个月时接受第二次肝活检。

在这些患者中,qHBcrAg与肝内cccDNA强相关,优于qHBsAg和HBV DNA。在IT,IC,LR和再激活阶段的患者中也观察到类似的发现。

在IC期第二次肝活检的32例ETV治疗的患者中,肝内cccDNA的下降伴随着qHBcrAg和qHBsAg的变化。然而,与qHBsAg相比,qHBcrAg的变化更强烈地与肝内cccDNA下降相关。

此研究表明,血清qHBcrAg可以作为CHB患者肝内HBV cccDNA令人满意的一种替代物。

原始出处:
Chen EQ, Feng S, et al. Serum hepatitis B core-related antigen is a satisfactory surrogate marker of intrahepatic covalently closed circular DNA in chronic hepatitis B. Sci Rep. 2017 Dec;7(1):173. doi: 10.1038/s41598-017-00111-0. 

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1642799, encodeId=2d281642e9929, content=<a href='/topic/show?id=bc4e85252f' target=_blank style='color:#2F92EE;'>#HBV-DNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8525, encryptionId=bc4e85252f, topicName=HBV-DNA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53b023016875, createdName=ms4657536712156177, createdTime=Sat Aug 19 15:49:00 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836620, encodeId=379d183662002, content=<a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8524, encryptionId=f9d08524be, topicName=HBV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Tue May 23 21:49:00 CST 2017, time=2017-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840976, encodeId=da4e18409e67a, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Tue Aug 29 08:49:00 CST 2017, time=2017-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=179720, encodeId=8e981e97200d, content=这个很有价值, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48ce1618316, createdName=stupidox, createdTime=Tue Mar 14 06:59:29 CST 2017, time=2017-03-14, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1642799, encodeId=2d281642e9929, content=<a href='/topic/show?id=bc4e85252f' target=_blank style='color:#2F92EE;'>#HBV-DNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8525, encryptionId=bc4e85252f, topicName=HBV-DNA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53b023016875, createdName=ms4657536712156177, createdTime=Sat Aug 19 15:49:00 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836620, encodeId=379d183662002, content=<a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8524, encryptionId=f9d08524be, topicName=HBV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Tue May 23 21:49:00 CST 2017, time=2017-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840976, encodeId=da4e18409e67a, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Tue Aug 29 08:49:00 CST 2017, time=2017-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=179720, encodeId=8e981e97200d, content=这个很有价值, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48ce1618316, createdName=stupidox, createdTime=Tue Mar 14 06:59:29 CST 2017, time=2017-03-14, status=1, ipAttribution=)]
    2017-05-23 klivis
  3. [GetPortalCommentsPageByObjectIdResponse(id=1642799, encodeId=2d281642e9929, content=<a href='/topic/show?id=bc4e85252f' target=_blank style='color:#2F92EE;'>#HBV-DNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8525, encryptionId=bc4e85252f, topicName=HBV-DNA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53b023016875, createdName=ms4657536712156177, createdTime=Sat Aug 19 15:49:00 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836620, encodeId=379d183662002, content=<a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8524, encryptionId=f9d08524be, topicName=HBV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Tue May 23 21:49:00 CST 2017, time=2017-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840976, encodeId=da4e18409e67a, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Tue Aug 29 08:49:00 CST 2017, time=2017-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=179720, encodeId=8e981e97200d, content=这个很有价值, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48ce1618316, createdName=stupidox, createdTime=Tue Mar 14 06:59:29 CST 2017, time=2017-03-14, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1642799, encodeId=2d281642e9929, content=<a href='/topic/show?id=bc4e85252f' target=_blank style='color:#2F92EE;'>#HBV-DNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8525, encryptionId=bc4e85252f, topicName=HBV-DNA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53b023016875, createdName=ms4657536712156177, createdTime=Sat Aug 19 15:49:00 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836620, encodeId=379d183662002, content=<a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8524, encryptionId=f9d08524be, topicName=HBV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Tue May 23 21:49:00 CST 2017, time=2017-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840976, encodeId=da4e18409e67a, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Tue Aug 29 08:49:00 CST 2017, time=2017-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=179720, encodeId=8e981e97200d, content=这个很有价值, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48ce1618316, createdName=stupidox, createdTime=Tue Mar 14 06:59:29 CST 2017, time=2017-03-14, status=1, ipAttribution=)]
    2017-03-14 stupidox

    这个很有价值

    0

相关资讯

乙肝疫苗后不产生抗体!这是为什么?

肝疫苗按规定时间接种了3次,但几个月后复查乙肝病毒五项指标,疫苗没有产生效果——乙肝表面抗体始终不产生。大概有以下几种情况:1、检测方法不精确:实际已产生抗体,但因检测方法不精确而致结果阴性。这时应当用最灵敏的方法,如酶联免疫法或放射免疫法来重新检测。因为有的地方检测方法不先进或不灵敏而得出假阴性结果。2、免疫反应太弱:机体对疫苗的免疫反应太弱,只产生微量的抗体,以至用先进的检测方法仍未能发现表面

预防乙肝母婴传播 五点关键

1、HBV DNA>2×106 U/ml方启用抗病毒药物预防乙肝母婴传播庄院士表示,目前各国乙肝防治指南或共识建议的抗病毒药物预防HBV母婴传播的孕妇血清HBV DNA阈值均在106 U/ml以上。AASLD指南特别指出对血清HBV DNA载量≤2×105 U/ml的孕妇,不建议用抗病毒药物降低HBV母婴传播风险。我国指南将抗病毒药物预防HBV母婴传播的阈值定为>2×106 U/ml。研究表明,孕

Hepatology:袁正宏教授发现宿主限制乙肝病毒复制及cccDNA表观调控的机制

日前,肝病学领域国际学术期刊《Hepatology》在线发表了复旦大学上海医学院基础医学院教育部/卫计委医学分子病毒学重点实验室袁正宏课题组联合上海市公共卫生临床中心科研人员题为“PRMT5 Restricts Hepatitis B Virus Replication via Epigenetic Repression of cccDNA Transcription and Interferen

Lancet Gastroen Heptaol:核苷酸类似物治疗的乙肝患者该不该添加干扰素治疗?

目前国际公认的两类有效抗病毒药物是干扰素(interferon, IFN)和核苷(酸)类似物(nucleos[t]ide analogues, NA)。核苷(酸)类似物虽然可以强效抑制HBV复制,但HBsAg清除率极低。既往的无对照研究的结果表明,HBeAg阴性的慢性乙型肝炎患者在接受核苷(酸)类似物抑制HBV复制时添加聚乙二醇干扰素,能增强HBsAg的清除。最近一期的The Lancet Gas

快速一览:2016年乙肝相关研究亮点汇总(TOP 10)

乙肝治愈方法也将很快到来。全世界2亿4000万人饱受乙型肝炎的折磨,乙型肝炎造成100万人死于肝衰竭和肝癌,乙肝治愈的需求达到了前所未有的水平。人们曾一度认为丙型肝炎是无法治愈的,而今天,新的治疗方法已经为丙型治愈带来了巨变。那么,乙肝治愈方法离我们有多远?本文梅斯医学编辑就2016年乙肝相关研究亮点进行汇总。【1】清华施一公院士PNAS发表乙肝新成果来自清华大学的研究人员对抗凋亡蛋白Bcl-

从艾滋到乙肝 血的教训能否刻入医生心中?

浙江某医院一名技术人员因违反“一人一管一抛弃”操作规程导致5名患者感染艾滋事件尚未平息,2月9日,网络不少媒体又曝光青岛某三级医院因该院血液透析室违反院感操作规程导致9名患者感染乙肝病毒。从艾滋到乙肝,医院为何一错再错?在浙江爆发的感染艾滋事件中,据说操作者就是存在一种侥幸心理。既然病人都经过了前期筛查,结果都正常,混用一下管子没有问题。这暴露了在院感防护中,当事人没有理解“把每一个工作都做到最严